167 related articles for article (PubMed ID: 36166003)
1. Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer.
Rochigneux P; Lisberg A; Garcia A; Granjeaud S; Madroszyk A; Fattori S; Gonçalves A; Devillier R; Maby P; Salem N; Gorvel L; Chanez B; Gukasyan J; Carroll J; Goldman J; Chretien AS; Olive D; Garon EB
Clin Cancer Res; 2022 Dec; 28(23):5136-5148. PubMed ID: 36166003
[TBL] [Abstract][Full Text] [Related]
2. Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy.
Riemann D; Turzer S; Ganchev G; Schütte W; Seliger B; Möller M
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830562
[TBL] [Abstract][Full Text] [Related]
3. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
7. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
8. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
9. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
Lo Russo G; Sgambelluri F; Prelaj A; Galli F; Manglaviti S; Bottiglieri A; Di Mauro RM; Ferrara R; Galli G; Signorelli D; De Toma A; Occhipinti M; Brambilla M; Rulli E; Triulzi T; Torelli T; Agnelli L; Brich S; Martinetti A; Dumitrascu AD; Torri V; Pruneri G; Fabbri A; de Braud F; Anichini A; Proto C; Ganzinelli M; Mortarini R; Garassino MC
ESMO Open; 2022 Dec; 7(6):100645. PubMed ID: 36455507
[TBL] [Abstract][Full Text] [Related]
10. Blood immune cell biomarkers in lung cancer.
Riemann D; Cwikowski M; Turzer S; Giese T; Grallert M; Schütte W; Seliger B
Clin Exp Immunol; 2019 Feb; 195(2):179-189. PubMed ID: 30246868
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
12. Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy.
Abed A; Beasley AB; Reid AL; Law N; Calapre L; Millward M; Lo J; Gray ES
ESMO Open; 2023 Dec; 8(6):102066. PubMed ID: 37995426
[TBL] [Abstract][Full Text] [Related]
13. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
14. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy.
Liu C; Jing W; An N; Li A; Yan W; Zhu H; Yu J
J Transl Med; 2019 Oct; 17(1):344. PubMed ID: 31623615
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
20. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA; Gainor JF; Callahan MK; Falchook GS; Pachynski RK; LoRusso P; Kummar S; Gibney GT; Burris HA; Tykodi SS; Rahma OE; Seiwert TY; Papadopoulos KP; Blum Murphy M; Park H; Hanson A; Hashambhoy-Ramsay Y; McGrath L; Hooper E; Xiao X; Cohen H; Fan M; Felitsky D; Hart C; McComb R; Brown K; Sepahi A; Jimenez J; Zhang W; Baeck J; Laken H; Murray R; Trehu E; Harvey CJ
Clin Cancer Res; 2022 Sep; 28(17):3695-3708. PubMed ID: 35511938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]